Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00287989
Completed
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving erlotinib together with paclitaxel and carboplatin may kill more tumor cells. PURPOSE: This randomized phase II trial is studying two different doses of erlotinib when given together with paclita... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
11/12/2018
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland +1 locations
Conditions: Lung Cancer
Register for Updates
Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer
NCT00102622
Terminated
The goal of this clinical research study is to find the highest safe dose of intraperitoneal tgDCC-E1A that can be given in combination with paclitaxel as a treatment for patients with recurrent, platinum-resistant ovarian cancer. How the cancer responds to this treatment will also be studied. Researchers will also ask the patients if they will allow additional tumor samples to be collected and extra blood samples to be drawn. These samples will be used to learn about the biological response bef... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/08/2018
Locations: University of Texas M. D. Anderson Cancer Center, Houston, Texas
Conditions: Ovarian Cancer
Register for Updates
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
NCT00733408
Completed
This phase II trial studies how well giving paclitaxel albumin-stabilized nanoparticle (Nab-paclitaxel) formulation together with bevacizumab followed by bevacizumab and erlotinib hydrochloride work in treating patients with metastatic breast cancer. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevac... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
11/06/2018
Locations: Anchorage Oncology Centre, Anchorage, Alaska +16 locations
Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Register for Updates
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
NCT02560038
Terminated
This trial is for people with bladder cancer that has spread. The purpose of this research study is to see if the chemotherapy combination of gemcitabine and cisplatin plus paclitaxel is safe and effective treatment for bladder cancer. Paclitaxel, gemcitabine and cisplatin have all been approved by the United States Food and Drug Administration (FDA). Gemcitabine and cisplatin is a standard treatment for bladder cancer. There have been studies that show that paclitaxel and cisplatin have antitu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/02/2018
Locations: UTHealth Memorial Hermann Cancer Center, Houston, Texas
Conditions: Urinary Bladder Neoplasms
Register for Updates
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
NCT00038246
Completed
The three study drugs (Thalidomide, Taxol, and Estramustine) used in this study are all chemotherapy drugs used in shrinking the cancer.
Gender:
MALE
Ages:
All
Trial Updated:
10/30/2018
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Prostate Cancer
Register for Updates
A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00038545
Completed
For patients with relapsed and refractory aggressive non-Hodgkin's lymphoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2018
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Non-Hodgkin's Lymphoma
Register for Updates
Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer
NCT02929576
Withdrawn
The purpose of this study is to evaluate and compare the clinical benefit and safety of treatment with enzalutamide in combination with paclitaxel chemotherapy or as monotherapy versus placebo with paclitaxel in patients with locally advanced or metastatic, diagnostic-positive, triple-negative breast cancer (TNBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2018
Locations: Not set, Topeka, Kansas +5 locations
Conditions: Breast Cancer
Register for Updates
Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla
NCT02626520
Terminated
Patients diagnosed with pancreatic cancer without clinically detectable metastatic disease will be treated with standardized systemic chemotherapy, followed by chemoradiation, and then surgical resection for those with resectable or borderline resectable disease. The primary endpoint is disease-free survival at 1 yr from initiation of treatment.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/12/2018
Locations: Essentia Health Cancer Center, Duluth, Minnesota
Conditions: Ductal Adenocarcinoma of Pancreas, Adenocarcinoma of Ampulla
Register for Updates
Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
NCT02138812
Terminated
Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase II dose (RP2D) of BAY1161909 in combination with paclitaxel in subjects with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2018
Locations: Not set, Santa Monica, California +5 locations
Conditions: Medical Oncology
Register for Updates
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
NCT01820325
Terminated
The Phase Ib part of the study aimed to determine the maximum tolerated dose/recommended Phase II dose (MTD/RP2D) of once daily buparlisib in combination with every-three-week carboplatin and paclitaxel in patients with previously untreated metastatic squamous NSCLC. The purpose of the Phase II portion of the study was to assess the treatment effect of adding buparlisib versus buparlisib-matching placebo to every-three-week carboplatin and paclitaxel on progression free survival (PFS) in patien... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/09/2018
Locations: Highlands Oncology Group, Fayetteville, Arkansas +6 locations
Conditions: Non-Small Cell Lunch Cancer
Register for Updates
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer
NCT02301988
Completed
This is a randomized, double-blind, placebo-controlled, multicenter, pre-operative Phase II study designed to estimate the efficacy of ipatasertib combined with paclitaxel chemotherapy versus placebo combined with paclitaxel chemotherapy in women with Stage Ia - IIIa triple-negative breast adenocarcinoma. The anticipated time on study treatment is 12 weeks.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/20/2018
Locations: Arizona Oncology Associates, PC-CASA, Tucson, Arizona +41 locations
Conditions: Breast Cancer
Register for Updates
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
NCT00064077
Completed
This randomized phase III trial is studying four combination chemotherapy regimens using cisplatin to compare how well they work in treating women with stage IVB, recurrent, or persistent cancer of the cervix. Drugs used in chemotherapy such as cisplatin, paclitaxel, vinorelbine, gemcitabine, and topotecan, use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen containing cisplatin is most effective in treating... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/18/2018
Locations: Gynecologic Oncology Group, Philadelphia, Pennsylvania
Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer
Register for Updates